GRAY News and Press, Graybug Vision Inc. From 03/13/21

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. A round of late-afternoon buying boosted the Dow Jones average to another record high on Friday as rising optimism around the global economic...

Wedbush analyst Liana Moussatos has downgraded shares of Grayburg Vision (GRAY) from outperform to neutral.She also cut her price target to $8 from $41.Moussatos writes that she is "perplexed" at secondary endpoint results from top-line data on the company's lead candidate, GB-102, for wet ag...

Gainers: Exela Technologies (XELA) +163%.Oragenics (OGEN) +47%.ReneSola (SOL) +42%.Auris Medical (EARS) +39%.The9 (NCTY) +37%.Canaan (CAN) +36%.AnPac Bio-Medical Science (ANPC) +36%.Riot Blockchain (RIOT) +35%.Washington Prime (WPG) +30%.Socket Mobile (SCKT) +23%.Losers: G...

Piper Sandler analyst Christopher Raymond has downgraded shares of Grayburg Vision (GRAY) to neutral from overweight.He has also cut his price target from $27 to $10.Raymond said the release earlier today of top-line data from  Grayburg's phase 2b ALTISSIMO study of GB-102, the company's...

Graybug Vision (GRAY) posts preliminary topline data from the 12-month treatment phase of its Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (wet AMD), the company's proprietary microparticle depot formulation of sunitinib malate injected int...

Median time to first supportive therapy was 5 months for GB-102 1mg 48% of patients in the GB-102 1 mg arm were rescue-free for at least 6 months Control of retinal thickness was consistent across all trial arms Mean best-corrected visual acuity with GB-102 1mg...

Graybug Vision (GRAY): FY GAAP EPS of -$5.25.Cash and cash equivalents of $33.42M.Press Release For further details see: Graybug Vision reports FY results

REDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate d...

REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced that Fred Guerar...

REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced the appointment ...